At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 673 enrolled
Drug / intervention
Upadacitinib +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Upadacitinib, Dupilumab, and 2 other interventions for Atopic Dermatitis. Completed, enrolled 673 participants across 159 sites in 23 countries.
Detailed Summary
This study will evaluate upadacitinib compared to dupilumab (Dupixent®) in adults with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, Canada, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Malaysia, Netherlands, New Zealand, Norway, Poland, Singapore, Spain, Sweden, Taiwan, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartFeb 2019
Primary CompletionAug 2020
Study CompletionDec 2020
TodayJul 2026
First PostedNov 13, 2018
Enrollment StartFeb 21, 2019
Primary CompletionAug 27, 2020
Study CompletionDec 9, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.6 years ago
Interventions
Upadacitinibbiological
Extended release tablet
Dupilumabbiological
Dupilumab is administered as a subcutaneous (SC) injection
Placebo to dupilumabdrug
Placebo administered as a subcutaneous injection
Placebo to upadacitinibdrug
Tablet